AB Science Past Earnings Performance
Past criteria checks 0/6
AB Science has been growing earnings at an average annual rate of 15.5%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been declining at an average rate of 12.7% per year.
Key information
15.5%
Earnings growth rate
21.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | -12.7% |
| Return on equity | n/a |
| Net Margin | -558.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How AB Science makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -6 | 3 | 6 |
| 31 Mar 24 | 1 | -9 | 3 | 8 |
| 31 Dec 23 | 1 | -12 | 4 | 10 |
| 30 Sep 23 | 1 | -14 | 3 | 11 |
| 30 Jun 23 | 1 | -17 | 3 | 12 |
| 31 Mar 23 | 1 | -15 | 3 | 13 |
| 31 Dec 22 | 1 | -14 | 4 | 13 |
| 30 Sep 22 | 1 | -15 | 4 | 14 |
| 30 Jun 22 | 1 | -17 | 4 | 14 |
| 31 Mar 22 | 2 | -16 | 4 | 13 |
| 31 Dec 21 | 2 | -14 | 4 | 11 |
| 30 Sep 21 | 2 | -13 | 4 | 12 |
| 30 Jun 21 | 2 | -11 | 3 | 12 |
| 31 Mar 21 | 2 | -13 | 3 | 12 |
| 31 Dec 20 | 2 | -15 | 3 | 13 |
| 30 Sep 20 | 2 | -16 | 3 | 12 |
| 30 Jun 20 | 2 | -18 | 3 | 12 |
| 31 Mar 20 | 2 | -20 | 3 | 14 |
| 31 Dec 19 | 2 | -22 | 3 | 16 |
| 30 Sep 19 | 2 | -25 | 3 | 19 |
| 30 Jun 19 | 2 | -28 | 3 | 23 |
| 31 Mar 19 | 2 | -27 | 3 | 25 |
| 31 Dec 18 | 2 | -26 | 3 | 27 |
| 30 Sep 18 | 2 | -25 | 3 | 27 |
| 30 Jun 18 | 2 | -25 | 3 | 27 |
| 31 Mar 18 | 2 | -26 | 3 | 27 |
| 31 Dec 17 | 2 | -27 | 3 | 27 |
| 30 Sep 17 | 2 | -27 | 3 | 26 |
| 30 Jun 17 | 2 | -26 | 3 | 26 |
| 31 Mar 17 | 2 | -27 | 3 | 27 |
| 31 Dec 16 | 2 | -28 | 3 | 28 |
| 30 Sep 16 | 2 | -28 | 4 | 27 |
| 30 Jun 16 | 2 | -28 | 4 | 27 |
| 31 Mar 16 | 2 | -28 | 4 | 25 |
| 31 Dec 15 | 2 | -27 | 4 | 24 |
| 30 Sep 15 | 2 | -24 | 4 | 21 |
| 30 Jun 15 | 2 | -22 | 4 | 19 |
| 31 Mar 15 | 2 | -19 | 4 | 16 |
| 31 Dec 14 | 2 | -16 | 4 | 13 |
| 30 Sep 14 | 2 | -16 | 4 | 13 |
| 30 Jun 14 | 2 | -15 | 3 | 13 |
| 31 Mar 14 | 2 | -15 | 3 | 12 |
| 31 Dec 13 | 2 | -15 | 3 | 12 |
Quality Earnings: 0Q77 is currently unprofitable.
Growing Profit Margin: 0Q77 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0Q77 is unprofitable, but has reduced losses over the past 5 years at a rate of 15.5% per year.
Accelerating Growth: Unable to compare 0Q77's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0Q77 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.2%).
Return on Equity
High ROE: 0Q77's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.